Dronedarone

A new antiarrhythmic agent for the treatment of atrial fibrillation

Danielle Garcia, Angela Cheng-Lai

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In the armamentarium for rhythm control, amiodarone has been a mainstay of therapy for the management of atrial fibrillation (AF). Although amiodarone has shown to be effective in maintaining sinus rhythm, it has many extracardiac adverse effects. Dronedarone, a benzofuran amiodarone derivative, is structurally modified to reduce toxicities often associated with chronic amiodarone therapy. With the addition of a methylsulfonyl group, dronedarone is less lipophilic, has lower tissue accumulation, and a much shorter serum half-life of 24 hours compared with amiodarone. Dronedarone is also designed without the iodine moieties that are responsible for thyroid dysfunctions associated with amiodarone. Similar to amiodarone, dronedarone exhibits electrophysiologic characteristics of all 4 Vaughan Williams classifications. Phase III clinical trials have shown dronedarone to be effective at reducing ventricular rate, reducing recurrence of AF, and reducing cardiovascular morbidity and mortality in patients with AF or atrial flutter (AFL). However, dronedarone was associated with increased mortality in one study that included patients with severe heart failure (HL) and left ventricular dysfunction. Overall, dronedarone appears to be well tolerated. The most common side effects are gastrointestinal in nature and include nausea, vomiting, and diarrhea. Because of its more favorable adverse effect profile, dronedarone is likely to be a useful addition to the therapeutic management of AF. However, further comparative studies with amiodarone are needed to define dronedarones place in therapy more clearly.

Original languageEnglish (US)
Pages (from-to)230-234
Number of pages5
JournalCardiology in Review
Volume17
Issue number5
DOIs
StatePublished - Sep 2009

Fingerprint

Amiodarone
Atrial Fibrillation
Therapeutics
dronedarone
Phase III Clinical Trials
Atrial Flutter
Mortality
Left Ventricular Dysfunction
Iodine
Nausea
Vomiting
Half-Life
Diarrhea
Thyroid Gland
Heart Failure
Morbidity
Recurrence
Serum

Keywords

  • Amiodarone
  • Antiarrhythmic
  • Atrial fibrillation
  • Atrial flutter
  • Dronedarone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dronedarone : A new antiarrhythmic agent for the treatment of atrial fibrillation. / Garcia, Danielle; Cheng-Lai, Angela.

In: Cardiology in Review, Vol. 17, No. 5, 09.2009, p. 230-234.

Research output: Contribution to journalArticle

@article{6dc444e750674427b42411e8c5899f51,
title = "Dronedarone: A new antiarrhythmic agent for the treatment of atrial fibrillation",
abstract = "In the armamentarium for rhythm control, amiodarone has been a mainstay of therapy for the management of atrial fibrillation (AF). Although amiodarone has shown to be effective in maintaining sinus rhythm, it has many extracardiac adverse effects. Dronedarone, a benzofuran amiodarone derivative, is structurally modified to reduce toxicities often associated with chronic amiodarone therapy. With the addition of a methylsulfonyl group, dronedarone is less lipophilic, has lower tissue accumulation, and a much shorter serum half-life of 24 hours compared with amiodarone. Dronedarone is also designed without the iodine moieties that are responsible for thyroid dysfunctions associated with amiodarone. Similar to amiodarone, dronedarone exhibits electrophysiologic characteristics of all 4 Vaughan Williams classifications. Phase III clinical trials have shown dronedarone to be effective at reducing ventricular rate, reducing recurrence of AF, and reducing cardiovascular morbidity and mortality in patients with AF or atrial flutter (AFL). However, dronedarone was associated with increased mortality in one study that included patients with severe heart failure (HL) and left ventricular dysfunction. Overall, dronedarone appears to be well tolerated. The most common side effects are gastrointestinal in nature and include nausea, vomiting, and diarrhea. Because of its more favorable adverse effect profile, dronedarone is likely to be a useful addition to the therapeutic management of AF. However, further comparative studies with amiodarone are needed to define dronedarones place in therapy more clearly.",
keywords = "Amiodarone, Antiarrhythmic, Atrial fibrillation, Atrial flutter, Dronedarone",
author = "Danielle Garcia and Angela Cheng-Lai",
year = "2009",
month = "9",
doi = "10.1097/CRD.0b013e3181b15ab9",
language = "English (US)",
volume = "17",
pages = "230--234",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Dronedarone

T2 - A new antiarrhythmic agent for the treatment of atrial fibrillation

AU - Garcia, Danielle

AU - Cheng-Lai, Angela

PY - 2009/9

Y1 - 2009/9

N2 - In the armamentarium for rhythm control, amiodarone has been a mainstay of therapy for the management of atrial fibrillation (AF). Although amiodarone has shown to be effective in maintaining sinus rhythm, it has many extracardiac adverse effects. Dronedarone, a benzofuran amiodarone derivative, is structurally modified to reduce toxicities often associated with chronic amiodarone therapy. With the addition of a methylsulfonyl group, dronedarone is less lipophilic, has lower tissue accumulation, and a much shorter serum half-life of 24 hours compared with amiodarone. Dronedarone is also designed without the iodine moieties that are responsible for thyroid dysfunctions associated with amiodarone. Similar to amiodarone, dronedarone exhibits electrophysiologic characteristics of all 4 Vaughan Williams classifications. Phase III clinical trials have shown dronedarone to be effective at reducing ventricular rate, reducing recurrence of AF, and reducing cardiovascular morbidity and mortality in patients with AF or atrial flutter (AFL). However, dronedarone was associated with increased mortality in one study that included patients with severe heart failure (HL) and left ventricular dysfunction. Overall, dronedarone appears to be well tolerated. The most common side effects are gastrointestinal in nature and include nausea, vomiting, and diarrhea. Because of its more favorable adverse effect profile, dronedarone is likely to be a useful addition to the therapeutic management of AF. However, further comparative studies with amiodarone are needed to define dronedarones place in therapy more clearly.

AB - In the armamentarium for rhythm control, amiodarone has been a mainstay of therapy for the management of atrial fibrillation (AF). Although amiodarone has shown to be effective in maintaining sinus rhythm, it has many extracardiac adverse effects. Dronedarone, a benzofuran amiodarone derivative, is structurally modified to reduce toxicities often associated with chronic amiodarone therapy. With the addition of a methylsulfonyl group, dronedarone is less lipophilic, has lower tissue accumulation, and a much shorter serum half-life of 24 hours compared with amiodarone. Dronedarone is also designed without the iodine moieties that are responsible for thyroid dysfunctions associated with amiodarone. Similar to amiodarone, dronedarone exhibits electrophysiologic characteristics of all 4 Vaughan Williams classifications. Phase III clinical trials have shown dronedarone to be effective at reducing ventricular rate, reducing recurrence of AF, and reducing cardiovascular morbidity and mortality in patients with AF or atrial flutter (AFL). However, dronedarone was associated with increased mortality in one study that included patients with severe heart failure (HL) and left ventricular dysfunction. Overall, dronedarone appears to be well tolerated. The most common side effects are gastrointestinal in nature and include nausea, vomiting, and diarrhea. Because of its more favorable adverse effect profile, dronedarone is likely to be a useful addition to the therapeutic management of AF. However, further comparative studies with amiodarone are needed to define dronedarones place in therapy more clearly.

KW - Amiodarone

KW - Antiarrhythmic

KW - Atrial fibrillation

KW - Atrial flutter

KW - Dronedarone

UR - http://www.scopus.com/inward/record.url?scp=70349140020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349140020&partnerID=8YFLogxK

U2 - 10.1097/CRD.0b013e3181b15ab9

DO - 10.1097/CRD.0b013e3181b15ab9

M3 - Article

VL - 17

SP - 230

EP - 234

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 5

ER -